Companies / Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc.

Nasdaq: TNYACIK 1858848SOUTH SAN FRANCISCO, CA

Financials

Revenue
Net income$-90.60M
Total debt
Cash$78.08M
Diluted EPS$-0.59
Shares outstanding224.2M

Ownership

224.2M shares outstanding · as of Jul 30, 2026
0.35%Insiders
Ownership
Insiders0.35%781,774
Institutions32.50%72,883,009
Public float67.15%150,565,229

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 12

View all →
Insider% of sharesShares
Ali FarazCEOChief Executive Officer · Director
0.20%443,404
Tingley WhittemoreChief Medical Officer
0.10%218,618
Higa TomohiroSVP, Finance
0.05%119,752
0.00%0
Kutzkey Tim10% owner

Institutional holders 99

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Renaissance Technologies LLC
13F manager
AddCommon Stock$1.29M+1.9M
+100.65%
3,713,761
1.66% of shares
low
Q1 2024
as of
Barclays PLC
13F manager
AddCommon Stock$1.09M+208K
+312.70%
274,013
0.12% of shares
low
Q1 2026
as of
Marshall Wace, LLP
13F manager
AddCommon Stock$896.6K+1.3M
+92.41%
2,705,390
1.21% of shares
low
Q2 2026
as of
Alphabet Inc.
13F manager
ExitCommon Stock$-650.2K-916K
-100.00%
low
Q3 2023
as of
Barclays PLC
13F manager
AddCommon Stock$613.1K+240K
+2635.78%
249,558
0.11% of shares
low
Q4 2023
as of
Barclays PLC
13F manager
TrimCommon Stock$-593.4K-183K
-73.39%
66,395
0.03% of shares
low
Q1 2026
as of
Millennium Management LLC
13F manager
AddCommon Stock$582.3K+841K
+18.22%
5,456,666
2.43% of shares
low
Q4 2024
as of
Barclays PLC
13F manager
TrimCommon Stock$-264.3K-185K
-68.59%
84,627
0.04% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TNYACommon StockEquity87990A106BBG00FPMK2S3